Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Melanoma

12 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCMEL15137

    07/21/2015

    Characterizing the Cardiometabolic Implications of Immune Therapy

    Basic Science

    VICCMEL15148

    03/13/2014

    Investigating Immune Responses in Patients with Advanced Melanoma Treated with Immune-Based Therapy

    Basic Science

    VICCMEL09109

    06/03/2010

    Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy

    Basic Science

    VICCMEL0287

    05/06/2003

    Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository

    Other

    VICCMEL14103

    08/17/2015

    A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

    Treatment

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    ECOGMELEA6141

    05/10/2016

    Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    ECOGMELS1404

    12/01/2015

    A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCMEL1471

    02/04/2015

    A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

    Treatment

    VICCMEL1457

    01/19/2015

    A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations


    Print this page for your doctor